| 000 | 01507 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515030226.0 | ||
| 264 | 0 | _c20060929 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a0022-3549 | ||
| 024 | 7 |
_a10.1002/jps.20592 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKortejärvi, H | |
| 245 | 0 | 0 |
_aLevel A in vitro-in vivo correlation (IVIVC) model with Bayesian approach to formulation series. _h[electronic resource] |
| 260 |
_bJournal of pharmaceutical sciences _cJul 2006 |
||
| 300 |
_a1595-605 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAnti-Arrhythmia Agents _xblood |
| 650 | 0 | 4 | _aBayes Theorem |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 |
_aCardiotonic Agents _xblood |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDelayed-Action Preparations |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrazones _xblood |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 |
_aPhosphates _xchemistry |
| 650 | 0 | 4 |
_aPyridazines _xblood |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSimendan |
| 650 | 0 | 4 | _aSolubility |
| 650 | 0 | 4 |
_aVasodilator Agents _xblood |
| 700 | 1 | _aMalkki, J | |
| 700 | 1 | _aMarvola, M | |
| 700 | 1 | _aUrtti, A | |
| 700 | 1 | _aYliperttula, M | |
| 700 | 1 | _aPajunen, P | |
| 773 | 0 |
_tJournal of pharmaceutical sciences _gvol. 95 _gno. 7 _gp. 1595-605 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/jps.20592 _zAvailable from publisher's website |
| 999 |
_c16329739 _d16329739 |
||